@drcilento
Personalized intensification of treatment for hormone-sensitive prostate cancer @NatRevClinOncol
Goal: hit cancer harder, earlier & smarter with biology, risk & PSMA-PET. ADT+ARPI = backbone for most pts.
Docetaxel for de novo high-volume.
Prostate RT: survival boost in low-volume.
Enzalutamide±ADT: best for high-risk BCR.
🌟PSMA-PET reshapes staging, EMBARK showed M1 in 46% despite negative CT/Bone scan (~30-40% higher detection)
Next discussions: integrating 177Lu-PSMA, AKT & PARP inhibitors after +ve trials with biomarkers as the key to pt selection ✅
Really nice review
doi.org/10.1038/s41571… @OncoAlertView quoted post on X
New online! Personalized intensification of treatment for hormone-sensitive prostate cancer nature.com/articles/s4157…View quoted post on X
www.nature.com Geographic and age variations in mutational processes in colorectal cancer Nature - Analysis of genomic data from 981 colorectal cancers from participants in 11 countries reveals variations in mutational signatures of microsatellite-stable cancers that are dependent on... 🌟A huge thank you to our amazing speakers & everyone who joined us for our special Seminar on Wed to announce the Awardees of the SA #Multiomics Framework Initiative @BioplatformsAus & celebrate their groundbreaking projects! 👏 We can't wait to see the impact of your work! 🚀🔬View quoted post on X
